
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is projected to see significant growth in product sales, with estimates of $1.73 billion for 2025, increasing to $2.15 billion in 2026, reflecting the successful expansion of its mRNA platform into various therapeutic areas. The company's efforts to enhance its balance sheet through a $1.5 billion debt deal will provide greater flexibility to navigate uncertainties while capitalizing on future opportunities. Additionally, improvements in manufacturing efficiency may lead to a gross margin rebound from 30% in 2023 back to 50% by 2025, further underpinning the company’s robust financial outlook.
Bears say
Moderna's financial outlook reflects significant challenges, particularly with a steep decline in COVID vaccine sales, which are projected to fall from $18 billion in 2022 to $6.7 billion in 2023, while future revenue from COVID-related products appears increasingly uncertain due to waning vaccination rates and competitive pressures in the respiratory vaccine market. The company has also adjusted its long-term financial expectations downward, with projected annual revenue from COVID vaccines diminishing from $3.5 billion to $2.5 billion as the pandemic transitions to an endemic phase. Additionally, ongoing negotiations within the EU suggest that sales opportunities may be limited, compounding the negative outlook for Moderna's revenue growth potential across its broader pipeline.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares